Therapeutic applications of Cytokines and Interferons are an emerging industry. Much attention is focused on the possibility of producing new drugs for use in cancer and autoimmune therapies. In a recent article written in Genetic Engineering News, (Recombinant IL-2 Therapies in The Clinic for Cancer and HIV, Nov. 1, 1997, Vol. 17, No. 19, pp. 1,8,34), clinical data was presented which cited successful evaluations of the therapeutic effects of these new recombinant chemistries. Clinical research labs in the United States, and worldwide, have demonstrated the value for the use of natural substances in human therapy. As with any new drug study, both the benefits and risks, are carefully considered. Despite side effects such as fever, nausea, vomiting and hypotension, the percentage of remissions and improvements in various disease states is significant. As many as 60% of study populations reported prompt responses within three weeks, with 50% of those still in remission for years (MD Anderson Cancer Center, Houston Texas).
Cell-Sci Corporation, (Alexandria, VA) promotes their Multikinetm product for head and neck cancer, also showing a three week response rate in study patients. A recent exhibition sponsored by Chiron Therapeutics, (Emeryville, CA), manufacturers of Proleukin(r) showed the successful results of several cytokine studies in renal cell carcinoma, metastatic melanoma, leukemia and AIDS. Other citations in the article came from NY Hospital-Cornell Medical Center and, internationally, at the Cancer Immunotherapy and Immunobiology Research Center in Jerusalem. Each of these studies showed favorable results when compared to traditional therapies. Each study also revealed the toxic side effects of higher doses of cytokines, when monitored post-injection. Current public studies are seeking distinct combinations of chemistries to reduce these side effects.
CYTIMMUNE SCIENCES, INC., (College Park, MD), has developed a patent pending method, the Cytokine Carrier System (CCStm). This method has demonstrated non-toxic administration to the system, resulting in the maintenance of drug levels inside therapeutic limits. The discovery brings to fruition a medical approach that works in harmony with the body's own defense mechanisms to eliminate disease and maintain health. Three major platform areas can be expanded into a number of therapeutic applications. These include use of the CCStm method : 1) in boosting cytokine levels to combat disease, 2) as a targeted cell delivery system for transport of drugs into the cell, and, 3) in reducing toxic levels of cytokine, typically produced by the hyperscretion of immune cells, through the use of anti-cytokine human monoclonal antibodies.
For additional information about the CCStm method, and its potential application for your organization, call (301)-445-4370 or visit our web site at http://www.cytimmune.com
###
RSS